Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

You are here: Home » News & Analysis

News & Analysis

Print

China biotech company and industry news and analysis...

Recent Articles

  Ascletis In-Licenses China Rights to an HCV Treatment from Medivir
  Harbin Gloria, WuXi Biologics Sign $818 Million Deal for Ex-China Rights to PD-1 Candidate
  Zai Lab Files for $115 Million IPO in the US
  Antengene of Shanghai Announces a $21 Million Series A Round
  Lilly Asia Ventures Closes Fourth Fund with $450 Million
  Shanghai Ankon Raises $100 Million to Market Pill-like Endoscopy Device
  Shenzhen Royal Asset to Pay $33 Million for Fibrosis Candidates from Prometic
  Zai Lab of Shanghai Plans $150 Million IPO in the US
  Fosun and Shanghai Pharmas Competing for $700 Million Stake in US-based Arbor
  Biocept Raises $2.2 Million from Ally Bridge; Plans China Expansion
 
Login